The timing of durvalumab administration affects the risk of pneumonitis in patients with locally advanced non-small cell lung cancer: a systematic review and meta-analysis.

Yang, Zhenyi; Zhong, Wen; Luo, Yixuan; Wu, Chunli

Yang, Zhenyi; Zhong, Wen; Luo, Yixuan; Wu, Chunli.

Afiliação

Yang Z; The Fourth Affiliated Hospital of China Medical University, Chongshan East Road #4, Huanggu District, Liaoning, 110032, China.
Zhong W; The Fourth Affiliated Hospital of China Medical University, Chongshan East Road #4, Huanggu District, Liaoning, 110032, China.
Luo Y; The Fourth Affiliated Hospital of China Medical University, Chongshan East Road #4, Huanggu District, Liaoning, 110032, China.
Wu C; The Fourth Affiliated Hospital of China Medical University, Chongshan East Road #4, Huanggu District, Liaoning, 110032, China. clwu@cmu.edu.cn.

BMC Cancer ; 23(1): 962, 2023 Oct 10.

Article em En | MEDLINE | ID: mdl-37817073

Assuntos

Carcinoma Pulmonar de Células não Pequenas; Neoplasias Pulmonares; Pneumonia; Humanos; Anticorpos Monoclonais/efeitos adversos; Quimiorradioterapia/efeitos adversos; Pneumonia/induzido quimicamente; Pneumonia/epidemiologia

Palavras-chave

Durvalumab; Non-small cell lung cancer; Radiotherapy; Time interval; meta- analysis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pneumonia / Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Tipo de estudo: Etiology_studies / Guideline / Risk_factors_studies / Systematic_reviews Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google